Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

FDA clears Liaison Plex Gram-negative blood culture assay

June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.

Visby gets clearance, CLIA waiver for POC respiratory test

June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.

Mayo Clinic, Kyan collaborate to expand access to cancer testing

June 2025—Mayo Clinic Laboratories and Kyan Technologies announced a collaboration to validate and provide Kyan’s Optim.AI across the United States. Optim.AI is an ex vivo drug sensitivity platform that combines small data AI and biological experiments. It provides insights into therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Labs will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options.

StatLab adds new U.S. manufacturing capabilities

June 2025—StatLab Medical Products announced that it is vertically integrating the production of containers and lids at its facility in Arlington, Tex., where the company currently produces nearly 100 million prefills annually, and will begin blow-molding gallon bottles in Q2. StatLab says it will also absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass.

Thermo Fisher launches NGS hybrid capture assay

June 2025—Thermo Fisher Scientific has introduced the One Lambda HybriType HLA Plus Typing Flex kit, a next-generation sequencing hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. The assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen class I and II genotyping analysis across various sample types, including whole blood and buccal swabs. It has a turnaround time of less than 5.5 hours, and the hands-on time is less than 2.5 hours. Data for the assay are analyzed using the company’s Type­Stream Visual NGS analysis software. The kit is for research use only.

Techcyte, Aiforia collaborate to advance AI-powered DP

June 2025—Techcyte and Aiforia announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories. The partnership brings together Techcyte’s Fusion digital pathology platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the Aiforia breast cancer suite. The companies say the partnership will continue to drive innovation in digital pathology, cancer diagnostics, and more with an expanding portfolio of AI applications.

Qiagen gets clearance for second QIAstat-Dx mini GI panel

June 2025—Qiagen announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. The panel focuses on bacterial infections covering Campylobacter, Salmonella, Shiga-like toxin-producing E. coli, Shigella, and Yersinia enterocolitica. It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers Campylobacter, Salmonella, STEC, Shigella, and norovirus. The panel runs on the QIAstat-Dx system and delivers results in about one hour with less than one minute of hands-on time.

Sysmex adds XQ-320 to its line of three-part diff analyzers

June 2025—Sysmex America announced the expansion of its three-part differential automated hematology analyzer line with the XQ-320 for CBC testing. The XQ-320 has a throughput of up to 70 samples per hour, provides results in less than 60 seconds, and is the company’s first three-part differential analyzer that includes BeyondCare Quality Monitor. The analyzer features 17 parameters including an absolute neutrophil count, optional manual discrimination within histograms for challenging samples, robust flagging, and a low aspiration volume of 16 μL. It requires minimal weekly maintenance and offers a quick shutdown and automatic wake-up function.

Bio-Rad gets EU QMS certificate for 40 QC products

May 2025—Bio-Rad Laboratories has received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling the CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. The controls are formulated with whole organisms in relevant matrices to simulate patient specimens. This design aims to ensure that the controls undergo the same workflow and process challenges as patient specimens during routine testing.

Revvity gets FDA approval for automated TB test

May 2025—Revvity announced that the FDA has approved the Auto-Pure 2400 liquid handling platform with the T-Spot.TB test, for in vitro diagnostic use. The Auto-Pure 2400 tests up to 24 samples per run and completes day-one T-Spot.TB workflows in less than three and a half hours.

MARKETPLACE

TRENDING